
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 3)*

Eyenovia, Inc.
(Name of Issuer)

Common Stock, \$0.0001 par value
(Title of Class of Securities)

30234E 104
(CUSIP Number)

Tsontcho Ianchulev
Curt LaBelle
295 Madison Avenue, Suite 2400
New York, NY 10017
917-289-1117

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

August 13, 2020
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or other subject to the liabilities of that section of Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names of Reporting Persons.	
	Tsoncho Ianchulev	
2	Check the Appropriate Box if a Member of a Group	
	(a) <input type="checkbox"/>	
	(b) <input type="checkbox"/>	
3	SEC Use Only	
4	Source of Funds (See Instructions)	
	PF	
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or Place of Organization	
	United States	
	7	Sole Voting Power
		1,069,635 ⁽¹⁾
	8	Shared Voting Power
		1,206,001 ⁽²⁾
	9	Sole Dispositive Power
		1,069,635 ⁽¹⁾
	10	Shared Dispositive Power
		1,206,001 ⁽²⁾
11	Aggregate Amount Beneficially Owned by Each Reporting Person	
	2,275,636 ⁽¹⁾⁽²⁾	
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares <input type="checkbox"/>	
13	Percent of Class Represented by Amount in Row (11)	
	10.7%	
14	Type of Reporting Person	
	IN	

(1) Includes (i) 508,679 shares of common stock, (ii) 457,917 shares of common stock underlying options and (iii) 41,216 shares of common stock underlying Class A warrants and (iv) 61,823 shares of common stock underlying Class B warrants held by Tsoncho Ianchulev directly that are exercisable within 60 days of the date of this report.

(2) Includes (i) 6,000 shares of common stock held by the Meliora Trust, (i) 606,667 shares of common stock and 140,000 shares of common stock underlying options held by Private Medical Equity, Inc. that are exercisable within 60 days of the date of this report and (ii) 453,334 shares of common stock held by PME Investor Services Eyenovia, LLC. Dr. Ianchulev and his wife are trustees and beneficiaries of the Meliora Trust. He is one of the two principal shareholders of Private Medical Equity, Inc. and a manager of PME Investor Services Eyenovia, LLC and, therefore, may be deemed to have beneficial ownership of the shares of common stock held by Private Medical Equity, Inc. and PME Investor Services Eyenovia, LLC.

1	Names of Reporting Persons.	
	Curt LaBelle	
2	Check the Appropriate Box if a Member of a Group	
	(a) <input type="checkbox"/>	
	(b) <input type="checkbox"/>	
3	SEC Use Only	
4	Source of Funds (See Instructions)	
	PF	
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or Place of Organization	
	United States	
	7	Sole Voting Power
		217,661 ⁽¹⁾
	8	Shared Voting Power
		1,200,001 ⁽²⁾
	9	Sole Dispositive Power
		217,661 ⁽¹⁾
	10	Shared Dispositive Power
		1,200,001 ⁽²⁾
11	Aggregate Amount Beneficially Owned by Each Reporting Person	
	1,417,662 ⁽¹⁾⁽²⁾	
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares <input type="checkbox"/>	
13	Percent of Class Represented by Amount in Row (11)	
	6.8%	
14	Type of Reporting Person	
	IN	

(1) Includes 27,985 shares of common stock and 189,676 shares underlying options held by Curt LaBelle directly that are exercisable within 60 days of the date of this report.

(2) Includes (i) 606,667 shares of common stock and 140,000 shares of common stock underlying options held by Private Medical Equity, Inc. that are exercisable within 60 days of the date of this report and (ii) 453,334 shares of common stock held by PME Investor Services Eyenovia, LLC. Dr. LaBelle is one of the two principal shareholders of Private Medical Equity, Inc. and a manager of PME Investor Services Eyenovia, LLC and, therefore, may be deemed to have beneficial ownership of the shares of common stock held by Private Medical Equity, Inc. and PME Investor Services Eyenovia, LLC.

1	Names of Reporting Persons.	
	Private Medical Equity, Inc.	
2	Check the Appropriate Box if a Member of a Group	
	(a) <input type="checkbox"/>	
	(b) <input type="checkbox"/>	
3	SEC Use Only	
4	Source of Funds (See Instructions)	
	WC	
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or Place of Organization	
	Nevada	
	7	Sole Voting Power
	8	746,667 ⁽¹⁾ Shared Voting Power
	9	0 Sole Dispositive Power
	10	746,667 ⁽¹⁾ Shared Dispositive Power
		0
11	Aggregate Amount Beneficially Owned by Each Reporting Person	
	746,667 ⁽¹⁾	
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares <input type="checkbox"/>	
13	Percent of Class Represented by Amount in Row (11)	
	3.6%	
14	Type of Reporting Person	
	CO	

(1) Includes 606,667 shares of common stock and 140,000 shares of common stock underlying options held by Private Medical Equity, Inc. that are exercisable within 60 days of the date of this report.

SCHEDULE 13D

This Amendment No. 3 on Schedule 13D amends the statement on Schedule 13D, dated February 14, 2018, which relates to the common stock, par value \$0.0001 per share (the "Common Stock") of Eyenovia, Inc. (the "Issuer"), as previously amended on Schedule 13D/A, dated January 2, 2019 and July 11, 2019 filed by:

Tsontcho Ianchulev
 Curt LaBelle
 Private Medical Equity, Inc., a Nevada corporation ("PME")

(collectively, PME with Drs. Ianchulev and LaBelle, the "Reporting Persons").

This Amendment No. 3 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of the change in outstanding shares of Common Stock of the Issuer as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended June 30, 2020, filed with the Securities and Exchange Commission (the "SEC") on August 14, 2020. Except as expressly amended below, the Schedule 13D, dated February 14, 2018, which was previously amended on January 2 and July 11, 2019, remains in effect.

Item 3. Source and Amount of Funds or Other Consideration.

On March 24, 2020, Dr. Ianchulev purchased 82,431 shares of Common Stock at a purchase price of \$2.27 per share, and also received 41,216 Class A Warrants (defined below) and 61,823 Class B Warrants (defined below) in the Issuer's offering of approximately \$6.0 million of units (the "Units"), with each Unit consisting of (i) one share of the Issuer's Common Stock, (ii) a one-year warrant to purchase 0.5 of a share of the Issuer's Common Stock ("Class A Warrant"), and (iii) a five-year warrant to purchase 0.75 of a share of the Issuer's Common Stock ("Class B Warrant").

Item 4. Purpose of the Transaction

The shares of Common Stock owned by the Reporting Persons have been acquired for investment purposes. The Reporting Persons may make further acquisitions of the Common Stock from time to time and, subject to certain restrictions, may dispose of any or all of the Common Stock held by the Reporting Persons at any time depending on an ongoing evaluation of the investment in such securities, prevailing market conditions, other investment opportunities and other factors.

On March 24, 2020, Dr. Ianchulev purchased 82,431 shares of Common Stock, at a purchase price of \$2.27 per share, and also received 41,216 Class A Warrants and 61,823 Class B Warrants in the Issuer's offering of approximately \$6.0 million of Units, with each Unit consisting of (i) one share of the Issuer's Common Stock, (ii) a one-year Class A warrant to purchase 0.5 of a share of the Issuer's Common Stock, and (iii) a five-year Class B warrant to purchase 0.75 of a share of the Issuer's Common Stock.

Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j) of Item 4 of this Amendment No. 3 to Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a)-(b) The aggregate number and percentage of Common Stock beneficially owned by the Reporting Persons (on the basis of a total of 20,536,431 shares of Common Stock outstanding as of August 13, 2020) are as follows:

Tsontcho Ianchulev

a)	Amount beneficially owned: 2,275,636	Percentage: 10.7%
b)	Number of shares to which the Reporting Person has:	
i.	Sole power to vote or to direct the vote:	1,069,635 ⁽¹⁾
ii.	Shared power to vote or to direct the vote:	1,206,001 ⁽²⁾
iii.	Sole power to dispose or to direct the disposition of:	1,069,635 ⁽¹⁾
iv.	Shared power to dispose or to direct the disposition of:	1,206,001 ⁽²⁾

(1) Includes (i) 508,679 shares of common stock, (ii) 457,917 shares of common stock underlying options and (iii) 41,216 shares of common stock underlying Class A Warrants and (iv) 61,823 shares of common stock underlying Class B Warrants held by Dr. Ianchulev directly that are exercisable within 60 days of the date of this report.

(2) Includes (i) 6,000 shares of Common Stock held by the Meliora Trust, (ii) 606,667 shares of Common Stock and 140,000 shares of Common Stock underlying options held by PME that are exercisable within 60 days of the date of this report and (iii) 453,334 shares of Common Stock held by PME Investor Services Eyenovia, LLC. Dr. Ianchulev is one of the two principal shareholders of PME and a manager of PME Investor Services Eyenovia, LLC and, therefore, may be deemed to have beneficial ownership of the shares of Common Stock held by PME and PME Investor Services Eyenovia, LLC.

Curt LaBelle

a)	Amount beneficially owned: 1,417,662	Percentage: 6.8%
b)	Number of shares to which the Reporting Person has:	
i.	Sole power to vote or to direct the vote:	217,661 ⁽¹⁾
ii.	Shared power to vote or to direct the vote:	1,200,001 ⁽²⁾
iii.	Sole power to dispose or to direct the disposition of:	217,661 ⁽¹⁾
iv.	Shared power to dispose or to direct the disposition of:	1,200,001 ⁽²⁾

(1) Includes 27,985 shares of Common Stock and 189,676 shares of Common Stock underlying options held by Dr. LaBelle directly that are exercisable within 60 days of the date of this report.

(2) Includes (i) 606,667 shares of Common Stock and 140,000 shares of Common Stock underlying options held by PME that are exercisable within 60 days of the date of this report and (ii) 453,334 shares of Common Stock held by PME Investor Services Eyenovia, LLC. Dr. LaBelle is one of the two principal shareholders of PME and a manager of PME Investor Services Eyenovia, LLC and, therefore, may be deemed to have beneficial ownership of the shares of Common Stock held by PME and PME Investor Services Eyenovia, LLC.

Private Medical Equity, Inc.

a)	Amount beneficially owned: 746,667	Percentage: 3.6%
b)	Number of shares to which the Reporting Person has:	
i.	Sole power to vote or to direct the vote:	746,667 ⁽¹⁾
ii.	Shared power to vote or to direct the vote:	0
iii.	Sole power to dispose or to direct the disposition of:	746,667 ⁽¹⁾
iv.	Shared power to dispose or to direct the disposition of:	0

(1) Includes 606,667 shares of Common Stock and 140,000 shares of Common Stock underlying options held by PME that are exercisable within 60 days of the date of this report.

(c) Each of the required transactions described in this Item 5(a) were reported on a Form 4 filed by Dr. Ianchulev with the SEC pursuant to Section 16 of the Act and are available on the SEC's website at www.sec.gov. The information reported in such filings is expressly incorporated herein.

Item 7. Material to be Filed as Exhibits

Exhibit 99.1* Joint Filing Agreement by and among the Reporting Persons.

* Filed previously.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 14, 2020

/s/ Tsontcho Ianchulev
Tsontcho Ianchulev

Date: August 14, 2020

/s/ Curt LaBelle
Curt LaBelle

Date: August 14, 2020

Private Medical Equity, Inc.

By: /s/ Tsontcho Ianchulev
Name: Tsontcho Ianchulev
Title: Member

By: /s/ Curt LaBelle
Name: Curt LaBelle
Title: Member
